Inflammation and auto-immunity: An update on the NOD-like receptors and their clinical role;Inflammation et auto-immunité: Les NOD-like receptors et leur impact en clinique

Revue Medicale Suisse

Volumn 4, Issue 155, 2008, Pages 1103-1106

  Gaide, Olivier ^a  

^a HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NOD LIKE RECEPTOR; TOLL LIKE RECEPTOR;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT ONSET STILL DISEASE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BARE LYMPHOCYTE SYNDROME; BLAU SYNDROME; CONTACT DERMATITIS; CROHN DISEASE; FAMILIAL MEDITERRANEAN FEVER; GOUT; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LUPUS ERYTHEMATOSUS; PATHOGENESIS; PROGNOSIS; PSEUDOGOUT; PYODERMA GANGRENOSUM; REVIEW; SENSOR; VITILIGO;

AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; NOD SIGNALING ADAPTOR PROTEINS; SKIN DISEASES;

EID: 44949229279     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: A trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006;27:352-7.
2. * Gaide O, Hoffman HM. Insight into the inflammasome and caspase-activating mechanisms. Expert Rev Clin Immunol 2008;4:61-77.
3. Sehgal VN, Srivastava G. Vitiligo : Auto-immunity and immune responses. Int J Dermatol 2006;45:583-90.
4. ** Jin Y, Mailloux CM, Gowan K, et al. NALPI in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007;356:1216-25.
5. Martinon F, Burns K, Tschopp J. The inflammasome : A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26.
6. Gauthier Y, Cario-Andre M, Lepreux S, Pain C, Taieb A. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 2003;148:95-101.
7. ** Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 2006;6:183-95.
8. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
9. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
10. Ryan JG, de Koning HD, Beck LA, et al. IL-1 blockade in Schnitzler syndrome: Ex vivo findings correlate with clinical remission. J Allergy Clin Immunol 2008; 121:260-2.
11. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
12. ** So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28.
13. Yu JW, Fernandes-Alnemri T, Datta P, et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 2007;28:214-27.
14. Watanabe H, Gaide O, Petrilli V, et al. Activation of the IL-1 beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007;127: 1956-63.
15. * Watanabe H, Gehrke S, Contassot E, et al. The inflammasome acts as a master switch between tolerance and sensitization. J Immunol 2008; In press.
16. Terheyden P, Kortum AK, Schulze HJ, et al. Chemo-immunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: Results of a nationwide survey of the German Dermatologic Cooperative Oncology Group. J Cancer Res Clin Oncol 2007;133:437-44.
17. Eckmann L, Karin M. NOD2 and Crohn's disease: Loss or gain of function? Immunity 2005;22:661-7.